Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Neurology Neuroimmunology & Neuroinflammation | March 26, 2021 | Volume: 8 | Issue: 3 | Pages: No page available
10.1212/nxi.0000000000000978
| PMID 33771837